Research-only: Gut / Inflammation (KPV + BPC-157)

Public • 2/6/2026

Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).

← Back Buy stack

Practical pre-check

Deterministic heuristics (stimulants, duplicates, hydration). Not medical advice.

Supplements

Items in this stack

Training load

Unknown load

Need more wearable data

Stimulant estimate

0 mg

Only counts explicit caffeine items

Looks clean

No obvious duplication/stimulant/hydration flags from the heuristic pass.

AI risk assessment

Context: No wearable data

No assessment yet.

Supplements

3 items

KPVLow

Daily • Other • Click to expand

Preclinical colitis models; limited human translation.

Buy ingredient →

1mg

Targeted KPV delivery for ulcerative colitis (preclinical)

Low

Population: Mouse ulcerative colitis models (DSS and TNBS)

Study type: Preclinical (animal + in vitro)

Dose context: —

Hyaluronic acid-functionalized nanoparticles loaded with KPV showed targeted delivery to colonic epithelial cells and macrophages, reducing inflammation in murine UC models; translational relevance to humans is not established.

Citation: Xiao et al., Mol Ther (2017) — Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles•https://pubmed.ncbi.nlm.nih.gov/28143741/

Colitis-associated cancer prevention (preclinical)

Low

Population: Mouse models (PepT1-expressing)

Study type: Preclinical (animal)

Dose context: —

KPV transported via PepT1 reduced colitis severity and prevented carcinogenesis in murine colitis-associated cancer models; no human trials identified.

Citation: Dalmasso et al., Inflamm Bowel Dis (2016) — Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of KPV•https://pubmed.ncbi.nlm.nih.gov/27458604/

Colitis severity reduction

Low

Population: Mouse colitis models + cellular models

Study type: Preclinical (cell + mouse)

Dose context: — • Duration: Preclinical protocol (see paper)

KPV showed anti-inflammatory effects mediated by PepT1 transport in intestinal epithelial/immune cells and reduced inflammation in mouse colitis models.

Citation: Dalmasso et al., Am J Physiol Gastrointest Liver Physiol (2008) — PepT1-mediated KPV uptake and colitis models•https://pubmed.ncbi.nlm.nih.gov/18061177/

BPC-157Low

Daily • Lyophilized • Click to expand

Preclinical GI models exist; robust clinical efficacy data lacking.

Buy ingredient →

1mg

Soft tissue healing signals (preclinical)

Low

Population: Animal models (multiple tissues)

Study type: Review (preclinical-focused)

Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/

Safety / pharmacokinetics

Low

Population: Healthy volunteers

Study type: Registered phase 1 trial (results not posted)

Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted and the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284

Musculoskeletal healing (preclinical)

Low

Population: Animal injury models (multiple tissues)

Study type: Narrative review of preclinical evidence

Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone and GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

Magnesium (Glycinate)Low

Daily • — • Click to expand

Added manually

Buy ingredient →

400mg

Insomnia in older adults (sleep latency, total sleep time)

Low

Population: Older adults with insomnia (3 RCTs, n=151)

Study type: Systematic review & meta-analysis

Dose context: 320 mg typical (range: 100–500 mg) • Duration: 8 weeks

Magnesium supplementation reduced sleep onset latency by ~17 min vs. placebo; increased sleep time and efficiency. Evidence rated low-to-very-low quality; all trials at moderate-to-high bias risk.

Citation: Mah J & Pitre T. BMC Complement Med Ther. 2021;21(1):125.•DOI: 10.1186/s12906-021-03297-z•https://pubmed.ncbi.nlm.nih.gov/33865376/

Benefit most plausible in those with low baseline magnesium. Dose refers to elemental magnesium.

Sleep quality in adults with poor sleep (magnesium bisglycinate RCT)

Moderate

Population: Adults aged 18–65 with self-reported poor sleep (n=155)

Study type: RCT (double-blind, placebo-controlled)

Dose context: 250 mg typical (range: 200–250 mg) • Duration: 8 weeks

250 mg elemental magnesium as bisglycinate modestly but significantly reduced Insomnia Severity Index score vs. placebo (−3.9 vs −2.3, p=0.049) by week 4; well-tolerated with minimal GI effects.

Citation: Abboud M et al. Nutrients. 2025.•https://pubmed.ncbi.nlm.nih.gov/40918053/

First RCT specifically using magnesium bisglycinate for sleep in a general adult population.